Closed Pfizer biopharma facility in Everett gets a new lease on life
The 270,000-square-foot campus had never opened after Pfizer bought Seagen, and Breakthrough said drugmakers have announced more than $600 billion in U.S. expansion plans.
4 Articles
4 Articles
Empty Everett office building sells for $78 million to out-of-state firm
EVERETT - A defunct, 270,000 square-foot office building, originally built for biomanufacturing, has been purchased for $78 million by a New York based financial venture, Breakthrough Properties, and includes a 21-year lease for a new, undisclosed tenant, according to a company press release. Breakthrough Properties announced it also secured a separate 21-year lease for the entire campus with a "global biopharma company", which the firm declined…
Closed Pfizer biopharma facility in Everett gets a new lease on life
A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with a new owner and a 21-year lease to an unnamed global biopharmaceutical company.
Breakthrough Properties Purchases Biomanufacturing Facility in Everett for $78 Million
Breakthrough Properties, a premier global life science real estate developer, today announced it has acquired a recently delivered biomanufacturing facility at 215 Shuksan Way in Everett, Washington, just outside of Seattle. In 2024, shortly after acquiring Seagen, Pfizer shut down the facility at this location, backing out of a 20-year lease. Breakthrough, a joint venture […]
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
